Nemunaitis J
Department of Clinical Research, Texas Oncology, Dallas, USA.
Semin Oncol. 1996 Apr;23(2 Suppl 4):9-14.
Over the past 2 years, the primary organ targeted for peripheral blood progenitor cell (PBPC) support after myeloablative chemotherapy or radiotherapy has shifted from the bone marrow to blood. Mobilization methods that involve chemotherapy, cytokines, or both have been identified. Optimal methods of mobilization have not yet been defined. This article reviews the studies in which recombinant human interleukin-3, recombinant human granulocyte colony-stimulating factor, and recombinant human granulocyte-macrophage colony-stimulating factor were used as single agents, in combination, or in sequence. The data support the conclusion that mobilization with cytokines alone is well tolerated and can be recommended as a potential method for mobilization of PBPCs. Specifically, sequential administration of recombinant human interleukin-3 and recombinant human granulocyte-macrophage colony-stimulating factor for mobilization of PBPCs may contribute to rapid platelet recovery after autologous transplantation.
在过去两年中，清髓性化疗或放疗后用于外周血祖细胞（PBPC）支持的主要靶器官已从骨髓转移到血液。已确定了涉及化疗、细胞因子或两者的动员方法。最佳动员方法尚未确定。本文回顾了使用重组人白细胞介素-3、重组人粒细胞集落刺激因子和重组人粒细胞-巨噬细胞集落刺激因子作为单一药物、联合使用或序贯使用的研究。数据支持以下结论：单独使用细胞因子进行动员耐受性良好，可作为动员PBPC的一种潜在方法推荐。具体而言，序贯给予重组人白细胞介素-3和重组人粒细胞-巨噬细胞集落刺激因子以动员PBPC可能有助于自体移植后血小板的快速恢复。
